The cytokeratin 17 expression in primary ovarian tumors has
diagnostic but not prognostic significance

J 2022

The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance

DUNDR, Pavel, Barbora BAZALOVA, Michaela BARTU, Tjalling BOSSE, Jana DROZENOVA et. al.

Basic information

Original name

The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance

Authors

DUNDR, Pavel (203 Czech Republic, guarantor), Barbora BAZALOVA (203 Czech Republic), Michaela BARTU (203 Czech Republic), Tjalling BOSSE, Jana DROZENOVA (203 Czech Republic), Pavel FABIAN (203 Czech Republic), Oluwole FADARE, Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Radek JAKSA (203 Czech Republic), Jan LACO (203 Czech Republic), Sigurd F. LAX, Radoslav MATEJ (203 Czech Republic), W Glenn MCCLUGGAGE, Gabor MEHES, Romana MICHALKOVA (203 Czech Republic), Kristyna NEMEJCOVA (203 Czech Republic), Naveena SINGH, Naveena SINGH, Simona STOLNICU, Petr SKAPA (203 Czech Republic), Marian SVAJDLER (203 Czech Republic) and Ivana STRUZINSKA (203 Czech Republic)

Edition

Virchows Archiv, New York, Springer, 2022, 0945-6317

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.500

RIV identification code

RIV/00216224:14110/22:00127202

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s00428-022-03338-z

UT WoS

000795504200001

Keywords in English

Cytokeratin 17; Ovarian tumors; Gastrointestinal tract tumors; Differential diagnosis

Abstract

V originále

We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0-11.4% of all tumors (including mucinous tumors, micropapillary serous borderline tumors, clear cell, endometrioid, and high-grade serous carcinomas). The only exception was low-grade serous carcinoma, where higher CK17 expression was present in 24% of cases. Concerning GIT tumors, the higher levels of CK 17 expression (in > 10% of tumor cells) were observed in the upper GIT tumors (68.5% of pancreatic ductal adenocarcinoma, 61.6% of gallbladder adenocarcinoma, and 46% of gastric adenocarcinoma), which differs substantially not only from most of the primary ovarian tumors, but also from colorectal carcinoma (3.7%; p < 0.001). The results of our study suggest that expression of CK17 can potentially be used as an adjunct marker in differential diagnosis between primary ovarian mucinous tumors and metastases from the upper GIT, but not from colorectal carcinoma. However, in GIT tumors, CK17 can be used in the differential diagnosis between adenocarcinomas of the upper and lower GIT. Statistical analysis did not reveal strong association of CK17 expression with clinicopathological variables or patient outcomes in any primary ovarian tumors.

Links

90125, large research infrastructures

Name: BBMRI-CZ III

Citovat

DUNDR, Pavel, Barbora BAZALOVA, Michaela BARTU, Tjalling BOSSE, Jana DROZENOVA, Pavel FABIAN, Oluwole FADARE, Jitka HAUSNEROVÁ, Radek JAKSA, Jan LACO, Sigurd F. LAX, Radoslav MATEJ, W Glenn MCCLUGGAGE, Gabor MEHES, Romana MICHALKOVA, Kristyna NEMEJCOVA, Naveena SINGH, Naveena SINGH, Simona STOLNICU, Petr SKAPA, Marian SVAJDLER and Ivana STRUZINSKA. The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance. Virchows Archiv. New York: Springer, 2022, vol. 481, No 2, p. 201-212. ISSN 0945-6317. Available from: https://dx.doi.org/10.1007/s00428-022-03338-z.

@article{2233282,
   author = {Dundr, Pavel and Bazalova, Barbora and Bartu, Michaela and Bosse, Tjalling and Drozenova, Jana and Fabian, Pavel and Fadare, Oluwole and Hausnerová, Jitka and Jaksa, Radek and Laco, Jan and Lax, Sigurd F. and Matej, Radoslav and McCluggage, W Glenn and Mehes, Gabor and Michalkova, Romana and Nemejcova, Kristyna and Singh, Naveena and Singh, Naveena and Stolnicu, Simona and Skapa, Petr and Svajdler, Marian and Struzinska, Ivana},
   article_location = {New York},
   article_number = {2},
   doi = {http://dx.doi.org/10.1007/s00428-022-03338-z},
   keywords = {Cytokeratin 17; Ovarian tumors; Gastrointestinal tract tumors; Differential diagnosis},
   language = {eng},
   issn = {0945-6317},
   journal = {Virchows Archiv},
   title = {The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance},
   url = {https://link.springer.com/article/10.1007/s00428-022-03338-z},
   volume = {481},
   year = {2022}
}

TY  - JOUR
ID  - 2233282
AU  - Dundr, Pavel - Bazalova, Barbora - Bartu, Michaela - Bosse, Tjalling - Drozenova, Jana - Fabian, Pavel - Fadare, Oluwole - Hausnerová, Jitka - Jaksa, Radek - Laco, Jan - Lax, Sigurd F. - Matej, Radoslav - McCluggage, W Glenn - Mehes, Gabor - Michalkova, Romana - Nemejcova, Kristyna - Singh, Naveena - Singh, Naveena - Stolnicu, Simona - Skapa, Petr - Svajdler, Marian - Struzinska, Ivana
PY  - 2022
TI  - The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance
JF  - Virchows Archiv
VL  - 481
IS  - 2
SP  - 201-212
EP  - 201-212
PB  - Springer
SN  - 09456317
KW  - Cytokeratin 17
KW  - Ovarian tumors
KW  - Gastrointestinal tract tumors
KW  - Differential diagnosis
UR  - https://link.springer.com/article/10.1007/s00428-022-03338-z
N2  - We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0-11.4% of all tumors (including mucinous tumors, micropapillary serous borderline tumors, clear cell, endometrioid, and high-grade serous carcinomas). The only exception was low-grade serous carcinoma, where higher CK17 expression was present in 24% of cases. Concerning GIT tumors, the higher levels of CK 17 expression (in > 10% of tumor cells) were observed in the upper GIT tumors (68.5% of pancreatic ductal adenocarcinoma, 61.6% of gallbladder adenocarcinoma, and 46% of gastric adenocarcinoma), which differs substantially not only from most of the primary ovarian tumors, but also from colorectal carcinoma (3.7%; p < 0.001). The results of our study suggest that expression of CK17 can potentially be used as an adjunct marker in differential diagnosis between primary ovarian mucinous tumors and metastases from the upper GIT, but not from colorectal carcinoma. However, in GIT tumors, CK17 can be used in the differential diagnosis between adenocarcinomas of the upper and lower GIT. Statistical analysis did not reveal strong association of CK17 expression with clinicopathological variables or patient outcomes in any primary ovarian tumors.
ER  -

DUNDR, Pavel, Barbora BAZALOVA, Michaela BARTU, Tjalling BOSSE, Jana DROZENOVA, Pavel FABIAN, Oluwole FADARE, Jitka HAUSNEROVÁ, Radek JAKSA, Jan LACO, Sigurd F. LAX, Radoslav MATEJ, W Glenn MCCLUGGAGE, Gabor MEHES, Romana MICHALKOVA, Kristyna NEMEJCOVA, Naveena SINGH, Naveena SINGH, Simona STOLNICU, Petr SKAPA, Marian SVAJDLER and Ivana STRUZINSKA. The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance. \textit{Virchows Archiv}. New York: Springer, 2022, vol.~481, No~2, p.~201-212. ISSN~0945-6317. Available from: https://dx.doi.org/10.1007/s00428-022-03338-z.

Detailed Information on Publication Record